$DVA

HHS Secretary Robert F. Kennedy Jr. announced a plan to reduce regulatory barriers in kidney care, aiming to increase competition and patient choice. The plan targets dialysis market dominance by DaVita and Fresenius Medical Care, which control 74% of the market, and proposes simplifying certification requirements. It also seeks to streamline kidney transplant processes and reduce financial barriers for living donors, but stops short of allowing direct compensation for organs.

DaVita, a kidney care provider, has rolled out a clinical innovation that improves dialysis treatment, bringing it closer to the function of a natural kidney. The company supports the Kidney Care National Plan and highlights its investments in technology and patient care. DaVita aims to address the organ shortage and improve outcomes for kidney disease patients.

DaVita (DVA) shares fell 7.1% after the Department of Health and Human Services released a new kidney care plan. The plan aims to increase competition and innovation in treatment markets, emphasizing preventive care. DaVita's stock closed at $175.08, down 6.4% from the previous close. The company reported Q4 revenue of $3.62 billion, a 9.9% YoY increase, and guided 2026 adjusted EPS with a midpoint of $14.30.

DaVita (DVA) and Fresenius Medical Care (FMS) shares fell on Tuesday after Axios reported the Trump administration plans to promote competition in the dialysis market. The move aims to reform the industry, potentially impacting the two leading providers.

Argus raised its target price for Tenet Healthcare (THC) to $294.00. The company operates 47 hospitals and over 500 outpatient facilities in the US, mainly in the South. This update may impact investor sentiment and trading activity for THC.

Berkshire Hathaway, led by Warren Buffett, owns 28 million shares of DaVita (DVA), worth $5.18 billion. DaVita's stock is up 58% this year. Berkshire has been reducing its stake, selling over 1.2 million shares in recent quarters. DaVita's aggressive share buybacks have increased Berkshire's ownership to over 45%. DaVita reported $3.55 billion in Q2 revenue and $4.02 EPS, up 55% year-over-year.

DaVita (DVA), Franklin Resources (BEN), and Archer Daniels Midland (ADM) have each gained over 30% YTD. DVA benefits from improved reimbursement rates and cost discipline, with analysts projecting 18% earnings growth. BEN has moderated outflows and beaten earnings estimates. ADM raised guidance despite volatile global trade conditions.

DaVita (DVA) shares rose 10% after the company raised its 2026 earnings guidance to $14.10-$15.20 per share, exceeding analyst estimates. The stock is now trading at $193.86 with a market cap of $12.41 billion. Analysts have a 'Moderate Buy' rating and an average price target of $233.43, suggesting 23% upside potential.

DaVita (DVA) announced that all global operations now use 100% renewable energy, as detailed in its 2025 Community Care Report. The company aims for net-zero scope 1 and 2 emissions by 2050. DaVita's shift to renewables is expected to improve efficiency and reduce costs in its dialysis centers, which are energy-intensive. The company has a market cap of approximately $11.6 billion.

DaVita, a Colorado-based medical firm, agreed to a $15 million settlement for a data breach lawsuit affecting 2.3 million patients. The fund, capped at $15 million, will provide payments up to $2,500 for documented losses and $50 for others, plus three years of credit monitoring. DaVita denies wrongdoing, and the claims process is not yet open.